Citigroup Has Lowered Expectations for Zenas BioPharma (NASDAQ:ZBIO) Stock Price

Zenas BioPharma (NASDAQ:ZBIO) had its price target reduced by Citigroup from $43.00 to $41.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s target price would suggest a potential upside of 78.03% from the stock’s current price.

ZBIO has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating and set a $44.00 price target on shares of Zenas BioPharma in a research note on Tuesday. Jefferies Financial Group reiterated a “buy” rating and issued a $48.00 price objective on shares of Zenas BioPharma in a research note on Tuesday, January 6th. Morgan Stanley increased their target price on Zenas BioPharma from $19.00 to $21.00 and gave the stock an “equal weight” rating in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Finally, Wall Street Zen raised Zenas BioPharma from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $44.14.

Zenas BioPharma Stock Performance

Shares of NASDAQ ZBIO opened at $23.03 on Tuesday. Zenas BioPharma has a 12 month low of $6.11 and a 12 month high of $44.60. The company has a market cap of $1.32 billion, a P/E ratio of -2.95 and a beta of -1.94. The business’s 50 day moving average is $22.91 and its two-hundred day moving average is $27.15. The company has a quick ratio of 5.66, a current ratio of 5.61 and a debt-to-equity ratio of 0.32.

Zenas BioPharma (NASDAQ:ZBIO) last released its earnings results on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($3.32).

Insider Buying and Selling at Zenas BioPharma

In other news, Director Hongbo Lu purchased 25,985 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The shares were acquired at an average price of $22.50 per share, for a total transaction of $584,662.50. Following the completion of the acquisition, the director directly owned 347,968 shares in the company, valued at approximately $7,829,280. The trade was a 8.07% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Patricia L. Allen bought 15,700 shares of Zenas BioPharma stock in a transaction dated Thursday, February 12th. The stock was acquired at an average cost of $24.85 per share, for a total transaction of $390,145.00. Following the purchase, the director directly owned 15,700 shares in the company, valued at approximately $390,145. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have bought 202,845 shares of company stock worth $3,747,185. Insiders own 16.50% of the company’s stock.

Institutional Trading of Zenas BioPharma

A number of large investors have recently made changes to their positions in ZBIO. SR One Capital Management LP increased its holdings in shares of Zenas BioPharma by 2.6% in the fourth quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock worth $182,924,000 after acquiring an additional 126,315 shares in the last quarter. NEA Management Company LLC lifted its holdings in shares of Zenas BioPharma by 28.9% during the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after purchasing an additional 789,500 shares in the last quarter. Federated Hermes Inc. lifted its holdings in shares of Zenas BioPharma by 45.9% during the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after purchasing an additional 853,740 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Zenas BioPharma by 25.0% in the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after purchasing an additional 290,307 shares during the period. Finally, Polar Capital Holdings Plc acquired a new position in shares of Zenas BioPharma in the 4th quarter valued at approximately $38,402,000.

More Zenas BioPharma News

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Company says funding supports continued development of obexelimab — a key clinical program that underpins long‑term value, which helps stabilize investor confidence. Zenas BioPharma Funding Supports Obexelimab Plans
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and kept a $44 price target, signaling strong upside from some sell‑side analysts and supporting bullish expectations. HC Wainwright Rating
• Neutral Sentiment: Citigroup trimmed its price target from $43 to $41 but maintained a “buy” rating — a modest downgrade to upside assumptions but not a change in overall endorsement. Citigroup Price Target Cut
• Neutral Sentiment: Morgan Stanley raised its target to $21 and kept an “equal weight”/Hold stance, reflecting a balanced near‑term view that recognizes pipeline potential but flags commercial and leverage uncertainties. Morgan Stanley / TipRanks Note
• Negative Sentiment: Quarterly results missed materially — Zenas reported EPS of ($4.54) vs. consensus of ($1.22). The magnitude of the miss increases short‑term downside risk and raises questions about near‑term cash burn and execution. Quarterly Earnings Press Release
• Negative Sentiment: New disclosure of an IPO‑related securities class action introduces additional financial and operational risk, which can pressure the stock while litigation remains unresolved. IPO-Related Class Action

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.